CLOSE
MENU
Young woman in white lab coat looking into microscope
Young woman in white lab coat looking into microscope

Investigator-Initiated Studies + Educational Grants

Improving Patient Care + Advancing Treatment Options

Bausch + Lomb recognizes that Investigator-Initiated Studies (IIS) enable research that has the potential to improve the treatment of disease, patient outcomes and the quality of health care. In general, IIS are smaller in scale than Phase IV trials, and are “proof of concept” or “exploratory” in nature. Bausch + Lomb is not the sponsor of these studies and they are not affiliated with the company’s clinical development programs. However, we believe that IIS can produce important contributions regarding our products or the therapeutic areas of interest to Bausch + Lomb .

Investigator Initiated Studies (IIS) empower the global research community to develop new treatments and technological advancements in ocular health. Research grants are funded by Bausch + Lomb to improve consumer standards of care, efficacy, patient satisfaction, safety and vision performance.

Our Investigator Initiated Studies (IIS) Program is conducted in accordance with the highest ethical standards and in full compliance with all applicable laws, regulations and guidelines. Approval of grant funding is never related to, or conditioned upon, past prescriptions or purchases of Bausch + Lomb products. Further, we do not offer or provide grants to encourage or to reward the prescription, purchase, ordering or recommending of our products.

Funding is awarded based on the scientific merit, alignment with company strategies and available funding. The IIS program is offered to all academic and community-based scientists who are interested in conducting their own research. The budget should reflect “fair market value” for all costs. We may provide monetary funding and product support.

Prior to submitting your IIS grant request, please be sure to thoroughly review the information below.

For technical assistance with the grant submission system, please submit a request for assistance here.

For questions related to the grant submission process, please email Bausch + Lomb Grants at caring@bausch.com.

Submit Funding Request Link-out icon

Our Mission

Bausch + Lomb is committed to improving the quality of life for patients and supporting the ongoing medical and scientific education of healthcare professionals and customers. Accordingly, Bausch + Lomb provides grants to support bona-fide scientific research. The Bausch + Lomb Grants Committee reviews and decides upon every application.

Our Mission

Bausch + Lomb is committed to improving the quality of life for patients and supporting the ongoing medical and scientific education of healthcare professionals and customers. Accordingly, Bausch + Lomb provides grants to support bona-fide scientific research. The Bausch + Lomb Grants Committee reviews and decides upon every application.

Strategic Areas of Interest

We welcome unsolicited research study proposals from qualified investigators in our strategic areas of interest which are listed below. If you have questions on any steps of the process or wish to discuss your study concept, please feel free reach out to a B+L contact (e.g. MSL, Medical Advisor, Medical Manager, Medical Director) for support or reach out to caring@bausch.com and we will connect you to a medical representative.

Pharmaceuticals

LUMIFY®

  • General safety data; longer-term safety data; Real-World use data regarding dose and duration

Blink® NutriTears

  • Use in consumer subgroups (e.g., contact lens wearers)
  • Early use/experience /use without AT
  • Real-World evidence on patient population, demographics, etc.
  • Gut microbiome/mechanism

Biotrue® Eye Drops

  • Data to support a quantitative "long-lasting" claim

Ocuvite®

  • Visual performance measures (e.g., MPOD)

Xipere®

  • Efficacy/safety of Xipere® in glaucoma patients/steroid responders
  • Use in Cystoid Macular Edema (CME) after cataract surgery
  • Durability of Xipere®

VYZULTA®

  • Real-World study in treatment-naive patients
  • Efficacy Vyzulta® in specific population, i.e, NTG
  • Efficacy of Vyzulta® post MIGS/SLT
  • Studies that highlight tolerability, safety and persistence with Vyzulta®
  • Real-World data on use after glaucoma surgery (demographics, etc.)
  • Real-World data on switch patients

COLD-FX®

  • Efficacy/safety/long-term studies in specific populations

MIEBO®

  • Use in contact lens wearers
  • Before/following refractive surgery
  • Use in contact lens users (not removing lenses or BID use)
  • Use with scleral lenses (Dr. Brocks, product only)
  • Effect on friction (lid wiper epitheliopathy)
  • Effect on biometry readings
  • Effect on visual aberrations/tear film dynamics
  • Imaging of corneal healing (Firefly)

XIIDRA®

  • Effect on comfort and dryness in symptomatic CL wearers
  • Use pre/post cataract surgery
  • Mechanism of Action (MOA) in a Dry Eye Disease (DED) T-cell activated mouse model
  • Effect on biomarkers in Dry Eye Disease (DED)
  • Retrospective study in patients who failed Restasis
  • Early clinical use/p atient-reported outcomes
  • Duration of use

COLD-FX® First Signs®

  • Efficacy when taken at first signs of cold or flu symptoms vs placebo

Artelac®

  • Early adaptors survey on various Artelac® launches
  • Retrospective chart reviews to understand patient characteristics, indications, etc. in different patient groups (glaucoma, etc.)

Artelac® Ultra 4S

  • Data on ocular effect of Fucoidan
  • Duration of use

PreserVision®/Ocuvite®

  • Real-World data on patient population, demographics

Artelace® Complete

  • Duration of use
  • Clinical evaluation & experience

Surgical

LuxSmart™ IOL

  • LuxSmart™ in monovision patients, expand the range of vision
  • LuxSmart™ in patients with mild glaucoma, early retinal changes

Optical Biometry & Topography System
(SeeNa™/Eyetelligence Software Platfom®)

  • Experiential SeeNA™ with Eyetel®, the connection between the two

Stellaris ELITE™ (Posterior Light Pipe)

  • Experiential, new design vs previous

Stellaris ELITE™ (Adaptive Fluidics)

  • Clinical benefits (Anterior)

IC-8® Apthera™ IOL

  •  Nomogram improvement

enVista® Envy IOL

  • Nomogram improvement

enVista® Aspire/IC-8® Apthera™/enVista® Envy IOL

  • Mix and match

Minimally Invasive Micro Sclerostomy (MIMS®)

  • Early clinical use/experience

MINTa™ (Minimally Invasive Nasal Trabeculostomy)

  • Early clinical use/experience

SeeLumaa™ Fully Digital Visualization

  • Clinical evaluation/experience

Vision Care

Contact Lens/Lens Care (ULTRA® One Day, INFUSE®, Biotrue®
Hydration Plus Multi-Purpose Solution, ULTRA® contact lenses)

  • Improving contact lens wear experience with patient education/coaching
  • Advancing ocular surface homeostasis and contact lens wear
  • Osmoprotectants, antioxidants, and humectants in contact lens products
  • Dual wear – benefits of contact lens and spectacle wear for satisfying patient needs

Contact Lens/Lens Care (Arise™ Ortho-K system)

  • Overnight Ortho-K wear

How to Apply

Investigator Initiated Studies are both clinical and nonclinical studies that are designed and managed by an investigator. The investigator assumes complete responsibility for study design and execution, as well as publication of study results. We welcome scientifically sound concepts to achieve strategic goals such as improving patient care or sparking new ideas for disease-related research.

The following information is required for IIS grant submission:

  • Study Title
  • Therapeutic Area
  • Indication
  • Product
  • Primary Investigator Information, including recent
  • Site Information
  • Proposal
  • Scientific Summary
  • Requested Funding
  • Requested Product
  • Planned Publication(s)

The following information is required for protocol submission:

  • Protocol
  • Final Budget

Post-IIS approval requirements include:

  • Final study protocol (including any amendments)
  • Final IRB approval letter for clinical submissions
  • If applicable, a copy of the IND/IDE approval or waiver from FDA

The following types of Investigator Initiated Studies (IIS) may be submitted

  • Clinical and nonclinical studies of approved product
  • Clinical and nonclinical observational studies, Real-World evidence (i.e., non-interventional studies)
  • Clinical and nonclinical studies requesting product only

Approved ISS could be funded through various methods, including monetary and/or product, as allowed under local laws and regulations. Our guidelines do not allow us to fund overhead in excess of 30% of the total budget.

Submit Funding Request Link-out icon

How to Apply

Investigator Initiated Studies are both clinical and nonclinical studies that are designed and managed by an investigator. The investigator assumes complete responsibility for study design and execution, as well as publication of study results. We welcome scientifically sound concepts to achieve strategic goals such as improving patient care or sparking new ideas for disease-related research.

The following information is required for IIS grant submission:

  • Study Title
  • Therapeutic Area
  • Indication
  • Product
  • Primary Investigator Information, including recent
  • Site Information
  • Proposal
  • Scientific Summary
  • Requested Funding
  • Requested Product
  • Planned Publication(s)

The following information is required for protocol submission:

  • Protocol
  • Final Budget

Post-IIS approval requirements include:

  • Final study protocol (including any amendments)
  • Final IRB approval letter for clinical submissions
  • If applicable, a copy of the IND/IDE approval or waiver from FDA

The following types of Investigator Initiated Studies (IIS) may be submitted

  • Clinical and nonclinical studies of approved product
  • Clinical and nonclinical observational studies, Real-World evidence (i.e., non-interventional studies)
  • Clinical and nonclinical studies requesting product only

Approved ISS could be funded through various methods, including monetary and/or product, as allowed under local laws and regulations. Our guidelines do not allow us to fund overhead in excess of 30% of the total budget.

Submit Funding Request Link-out icon

Frequently Asked Questions

Can individual physicians or groups of physicians in private practice request study funding?

Study requests from individual physicians or groups of physicians in private practice can be submitted for review.

How can I find the status of my study proposal?

You will receive an email confirmation once your proposal has been submitted. Please allow at least six weeks for proposal review. You may view your study proposal’s status by logging in to the system. Your saved or submitted proposals will be listed in the "My Projects” section of your dashboard.

What does it mean if the submission log reads “proposal evaluation”?

We have received your proposal and it is under review.

Can I save a proposal without submitting it?

Yes. You can save your proposal at any time by clicking on the “Save for Later” button. In addition, each time you move to another page, the entered information is saved. We recommend that you bookmark the login page so you may return to it easily.

If I want to amend my study, what do I do?

Please do not submit a new application to amend an active project; email Bausch + Lomb Grants at caring@bausch.com

When will I receive payment for the study milestones?

Once you submit a project status update, along with the associated invoice for a payable milestone, it may take up to 30 days for payment to be received. Please ensure all contact information is kept up to date to prevent any delay.